[en] Anti-inflammatory medications are known since a long time and still remain among the most used drugs in clinical practice. They belong to a variety of pharmacological classes and act via very different biochemical mechanisms. Nonsteroid anti-inflammatory drugs, which are derived from acetylsalicylic acid, and cortisone with its multiple derivative molecules (glucocorticoids) remain the background therapy of diseases associated with inflammation, either acute or chronic. Some old molecules, known to exert an anti-inflammatory activity, still have specific indications, colchicine and methotrexate as examples. However, the greatest innovation of the last two decades results from the launch of biological therapies, starting with the use of anti-TNF? agents to move towards monoclonal antibodies targeting various pro-inflammatory interleukins (IL-1, IL-6, IL-5, IL-17, IL-23, …). Finally, small molecules acting as JANUS kinase inhibitors or tyrosine kinase 2 inhibitors open new alternatives in severe diseases that are resistant to other anti-inflammatory drugs. The interest for anti-inflammatory medications has been reinforced since the COVID-19 outbreak.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques
Language :
French
Title :
Les médicaments anti-inflammatoires : des anciens classiques aux biothérapies et inhibiteurs de JAK.
Alternative titles :
[en] Anti-inflammatory drugs : from old classical ones to biotherapies and JAK inhibitors.
Publication date :
May 2022
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Be
Special issue title :
Inflammation et maladies inflammatoires chroniques
Nailwal NP, Doshi GM. Role of intracellular signaling pathways and their inhibitors in the treatment of inflammation. Inflammopharmacology 2021;29:617-40.
Sinniah A, Yazid S, Flower RJ. From NSAIDs to glucocorticoids and beyond. Cells 2021;10:3524.
Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007;42:3-27.
Smolen JS, Landewe RB, Bijlsma JW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685-99.
Whitehouse MW. Drugs to treat inflammation: a historical introduction. Curr Med Chem 2005;12:2931-42.
Rainsford KD. History and development of the salicylates. In: KD Rainsford, editor. Aspirin and related drugs. London & New York;2004: Taylor & Francis. p 1-23.
Chast F. Histoire de l'aspirine. Feuillets de Biologie 2017;337:49-57.
Cagnina A, Chabot O, Davin L, et al. L'athérosclérose, une maladie inflammatoire. Rev Med Liege 2022;77:302-9.
Becker G, Monassier L. Anti-inflammatoires non stéroïdiens: rappels pharmacologiques et évolutions récentes de l'état des connaissances. Médecine Thérapeutique 2018;24:240-8.
Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179-91.
Scheen AJ. Retrait du rofécoxib (Vioxx®): A propos de la sécurité cardiovasculaire des anti-inflammatoires non stéroïdiens COX-2 sélectifs. Rev Med Liege 2004;59:565-9.
Burns CM. The history of cortisone discovery and development. Rheum Dis Clin North Am 2016;42:1-14, vii.
Edwards C. Sixty years after Hench: corticosteroids and chronic inflammatory disease. J Clin Endocrinol Metab 2012;97:1443-51.
Chast F. Histoire de la corticothérapie. Rev Med Int 2013;34:258-63.
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
Quatrini L, Ugolini S. New insights into the cell- and tissue- specificity of glucocorticoid actions. Cell Mol Immunol 2021;18:269-78.
Doumeizel PM, Robin F, Ballerie A, et al. Effets indésirables de la corticothérapie orale au long cours. Rev Prat 2021;71:587-96.
Scheen AJ, Noël A, Delvenne P. Jérusalem G. Inflammation et cancer: une relation complexe à double sens. Rev Med Liege 2022;77:354-60.
Misset B, Parzibut G, Layios N, et al. Inflammation au cours de la COVID-19. Rev Med Liege 2022;77:277-84.
Martins CS, de Castro M. Generalized and tissue specific glucocorticoid resistance. Mol Cell Endocrinol 2021;530:111277.
McKenzie BJ, Wechalekar MD, Johnston RV, et al. Colchicine for acute gout. Cochrane Database Syst Rev 2021;8:CD006190.
Moutschen M.. Maladies auto-inflammatoires monogéniques. Une introduction sur un mode translationnel aux inflammasomopathies Rev Med Liege 2022;77:392-8.
Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease: in-depth review. Circulation 2022;145:61-78.
Yasmin F, Najeeb H, Moeed A, et al. Safety and efficacy of colchicine in COVID-19 patients: a systematic review and meta-analysis of randomized control trials. PLoS One 2022;17:e0266245.
Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-alpha. Clin Exp Rheumatol 2010;28:S3-8.
Malaviya AN. Low-dose methotrexate (LD-MTX) in rheumatology practice - A most widely misunderstood drug. Curr Rheumatol Rev 2016;12:168-76.
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020;16:145-54.
Kaiser MJ, Malaise MG. Comment je traite... Une polyarthrite rhumatoïde. L'avènement d'une nouvelle ère thérapeutique: les anticorps anti-TNF-alpha. Rev Med Liege 2002;57:486-92.
Malaise M, Chapelier N, Dewael T, et al. Une révolution thérapeutique en rhumatologie: oui, mais.... Rev Med Liege 2020;75:369-75.
Belaiche J, Louis E. Traitement de la maladie de Crohn de l'adulte par anticorps anti-tumour necrosis-alpha (TNF alpha). Rev Med Liege 2000;55:827-32.
D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021;70:1396-405.
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis 2020;14:4-22.
Reenaers C, Louis E. Nouveautés dans la prise en charge des maladies inflammatoires chroniques intestinales. Rev Med Liege 2022;77:323-9.
Libon F, Lebas E, El Hayderi L, et al. Les traitements actuels du psoriasis: de l'étanercept aux antagonistes anti-IL17 et -IL23. Rev Med Liege 2020;75:376-81.
Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network metaanalysis. Cochrane Database Syst Rev 2020;1:CD011535.
Rezk MF, Pieper B. Unlocking the value of anti-TNF biosimilars: reducing disease burden and improving outcomes in chronic immune-mediated inflammatory diseases: a narrative review. Adv Ther 2020;37:3732-45.
Ablamunits V, Lepsy C. Blocking TNF signaling may save lives in COVID-19 infection. Mol Biol Rep 2022;49:2303-09.
Siebert S, Tsoukas A, Robertson J, et al. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 2015;67:280-309.
Van Kemseke C, Louis E, Reenaers C. Védolizumab (Entyvio ®), nouveau traitement des maladies inflammatoires intestinales. Rev Med Liege 2015;70:575-82.
Schleich F, Graff S, Bougard N, et al. L'asthme bronchique en pratique clinique: des phénotypes inflammatoires au traitement personnalisé. Rev Med Liege 2022;77:289-94. 41 Gallagher A, Edwards M, Nair P, et al. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev 2021;10:CD012929.
Schleich F, Frix AN, Paulus V, et al. Une décennie d'avancées dans l'asthme: l'apport des biothérapies. Rev Med Liege 2020;75:350-55.
Varisco PA, So A. Une nouvelle option thérapeutique dans la prise en charge de l'inflammation chronique en rhumatologie: les inhibiteurs des Janus kinases. Rev Med Suisse 2014;10:187-91.
Matucci A, Vivarelli E, Nencini F, et al. Strategies targeting type 2 inflammation: from monoclonal antibodies to JAK-inhibitors. Biomedicines 2021;9:1497.
Tanaka Y, Luo Y, O'Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022;18:133-45.
Fragoulis GE, Brock J, Basu N, et al. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52.
Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache? Drugs 2020;80:1183-201.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:1637-45.
RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. 2022. Available from: https://www.medrxiv.org/content/10. 1101/2022.03.02.22271623v1.full.pdf
Hromadova D, Elewaut D, Inman RD, et al. From science to success? Targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases. Front Genet 2021;12:685280.
Gonciarz M, Pawlak-Bus K, Leszczynski P, et al. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy 2021;13:1135-50.
Bukstein DA, Luskin AT. Pharmacoeconomics of biologic therapy. Immunol Allergy Clin North Am 2017;37:413-30.
Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med 2021;385:628-39.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
